Description

HBT1 Powder

HBT1
CAS Number	489408-02-8
Molar Mass	386.39g.mol-1
Chemical Formula	C16H17F3N4O2S
IUPAC Name	2-(((5-Methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)amino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide

Introduction

HBT1 Powder stands as an exclusive research product meticulously designed for scientific exploration, emphasizing its application in research and explicitly excluding any connection to human consumption. This powdered form of HBT1 offers researchers a versatile tool to investigate its potential benefits in the realms of neurotrophic factors and neurological diseases.

Key Characteristics

HBT1 exhibits unique pharmacological characteristics that make it a focus of neuroscientific research. Its properties may impact factors related to brain health and neurological function, prompting interest in its potential applications.

Research Applications

HBT1 Powder finds diverse applications in research domains, serving as a valuable tool for investigating its potential benefits, with a particular emphasis on brain-derived neurotrophic factor (BDNF) modulation and its impact on neurological diseases.

Research Benefits

HBT1 on Brain-derived Neurotrophic Factor (BDNF)

Studies suggest that HBT1 may influence the levels of Brain-derived Neurotrophic Factor (BDNF), a key neurotrophin associated with neuronal survival, growth, and differentiation. Exploring HBT1’s impact on BDNF levels provides valuable insights into its potential neuroprotective and neuroregenerative effects.

HBT1 on Neurological Diseases

Preliminary research indicates that HBT1 may have potential applications in addressing neurological diseases. Investigations into its impact on conditions such as neurodegenerative disorders could pave the way for therapeutic advancements.

Summary

HBT1 Powder, designed exclusively for research purposes, offers researchers a unique avenue for investigating its potential benefits on brain-derived neurotrophic factor (BDNF) modulation and its potential applications in addressing neurological diseases. The distinctive characteristics of HBT1 make it a promising subject for further exploration in neuroscientific research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

Kunugi, Akiyoshi & Tajima, Yasukazu & Kuno, Haruhiko & Sogabe, Satoshi & Kimura, Haruhide. (2018). HBT1, a Novel AMPA Receptor Potentiator with Lower Agonistic Effect, Avoided Bell-Shaped Response in In Vitro BDNF Production. Journal of Pharmacology and Experimental Therapeutics. 364. jpet.117.245050. 10.1124/jpet.117.245050. [Read More]

Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015 Dec 10;11(6):1164-78. doi: 10.5114/aoms.2015.56342. Epub 2015 Dec 11. PMID: 26788077; PMCID: PMC4697050. [Read More]